Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis

Mult Scler. 2012 Mar;18(3):377-8. doi: 10.1177/1352458511418631. Epub 2011 Aug 9.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / metabolism
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / therapeutic use
  • Maximum Tolerated Dose
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Rituximab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab